艾美疫苗(06660.HK):EV71-CA16二價手足口病在研疫苗獲國家藥監局藥物臨牀試驗批准通知書
格隆匯10月31日丨艾美疫苗(06660.HK)發佈公吿,公司的全資附屬公司艾美康淮生物製藥(江蘇)有限公司於近日取得國家藥品監督管理局藥品審評中心關於EV71-CA16二價手足口病在研疫苗的藥物臨牀試驗批准通知書。
根據披露,在中國,手足口病是5歲以下兒童常見病。感染後1至2天內,手掌、腳底及口腔通常會出現皮疹,舌頭及牙齦可能會出現水泡。嚴重的手足口病在感染後數週內可導致脱甲病(手指甲及腳趾甲分離)。引起手足口病的病毒通常通過人與人之間的接觸、感染者的咳嗽及排泄以及被病毒污染的物體傳播。手足口病最常見的病原體分別是腸道病毒的兩個亞型:腸道病毒71型(EV71)及柯薩奇病毒A16型 (CA16)。集團的EV71-CA16二價手足口病在研疫苗同時針對EV71及CA16病毒株,可以增強對手足口病的防範。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.